Fresenius SE & Co. KGaA (FRA:FREA)
Germany · Delayed Price · Currency is EUR | Market Cap | 25.82B -3.9% |
| Revenue (ttm) | 23.28B +3.4% |
| Net Income | 1.52B +35.3% |
| EPS | 2.70 +35.3% |
| Shares Out | n/a |
| PE Ratio | 16.97 |
| Forward PE | 11.99 |
| Dividend | 0.17 (1.54%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | n/a |
| Open | 11.10 |
| Previous Close | 11.20 |
| Day's Range | 11.10 - 11.10 |
| 52-Week Range | 8.60 - 20.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod... [Read more]
Financial Performance
In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.
Financial StatementsNews
Fresenius Announces Climb In Q2 Bottom Line
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius (FSNPF.PK) reported a profit for its second quarter that Increases, from the same period last yearThe company's earnings totaled EUR382 million, or ...
Fresenius Raises 2026 Earnings Guidance on Strong Performance
Fresenius accelerates its growth trajectory, lifting 2026 earnings guidance as robust Q2 results, rising margins and solid segment performance underscore its strategic momentum.
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Forecast / Full year Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performa...
Fresenius Kabi: Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan (rituximab) Rituximab is a CD20-directed cytolytic antibody used across multip...
Fresenius Kabi: Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
U.S. FDA and EMA acceptance for review of Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, of intravenous vedolizumab biosimilar candidate, an integ...
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
BAD HOMBURG, Germany, July 23, 2026 /PRNewswire/ -- The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its ...
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Shares in several European and Asian makers of generic medicines fell after President Trump said the U.S. would place tariffs on such drugs starting in August 2028.
Fresenius posts profit beat in first quarter, confirms outlook
German healthcare group Fresenius beat analysts' adjusted operating profit expectations for the first quarter on Wednesday, citing a strong performance at its drug making division Kabi.
Fresenius SE Raises Guidance After Strong Kabi, Helios Performances
The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.
Healthcare group Fresenius tops Q4 operating profit expectations
Fresenius reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at...
Fresenius perfectly positioned to combat health inequality, says CEO
Michael Sen, CEO at Fresenius, explains what the company is doing to help close the health care gap.
Fresenius to assess whether state aid impacts bonus, dividend payouts
German healthcare group Fresenius said it was examining whether the state aid it received to help offset high energy costs at its hospitals business would bar it from making management bonus and divid...
Fresenius launches biosimilar version of AbbVie's Humira at 5% discount
The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price...
Germany's Fresenius to simplify structure, flags potential profit fall
German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the ...
Fresenius SE CEO to quit after earnings outlook sours
FRANKFURT (Reuters) -Fresenius SE said its long-serving Chief Executive Stephan Sturm would quit, to be replaced by the head of its drugs unit, after the diversified group's earnings were hit followin...
Healthcare group Fresenius raises 2021 forecasts
German healthcare group Fresenius raised 2021 targets though it saw a weaker third quarter, saying progress on its cost-cutting plan should offset troubles at its dialysis unit.
Fresenius CEO says second quarter was 'very strong,' driven by hospitals business
Stephan Sturm, chief executive officer of Fresenius, discusses the firm's second-quarter earnings.